• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. May 1994; 144(5): 927–937.
PMCID: PMC1887352

Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.

Abstract

The ability of interleukin-6 (IL-6) to modulate immune parameters and mesangial cell function suggests a role for this cytokine in the development of autoimmune glomerulonephritis. This hypothesis was tested in 6-month-old female (NZB x NZW)F1 mice that were administered recombinant human IL-6 (rhIL-6) (50 and 250 micrograms/kg s.c.) for 12 weeks, resulting in an accelerated and severe form of membranoproliferative glomerulonephritis associated with marked upregulation of mesangial major histocompatibility complex class II antigen and glomerular ICAM-1 expression. To distinguish direct effects of rhIL-6 on the renal mesangium from those mediated through the immune system, (NZB x NZW)F1 mice were immunosuppressed with cyclosporin. Immunosuppression by cyclosporin inhibited the development of glomerulonephritis, decreased class II antigen expression, and abrogated IL-6-mediated effects. Administration of neutralizing anti-IL-6 antibody had no effect on the spontaneous development of glomerulonephritis in (NZB x NZW)F1 mice. This finding, together with undetectable IL-6 serum levels, makes a pathogenetic role of endogenously produced IL-6 in this disease model unlikely. In contrast to (NZB x NZW)F1 mice, parental NZW or BALB/c mice given high doses of rhIL-6 (500 micrograms/kg) or recombinant murine IL-6 (100 micrograms/kg) daily for 4 weeks failed to develop morphological or biochemical evidence of glomerulonephritis. Induction of acute phase proteins, anemia, thrombocytosis, and induction of renal class II antigen confirmed the biological activity of IL-6 in these mice. In conclusion, while non-nephritogenic in normal mice, IL-6 accelerates the development of the genetically determined glomerulonephritis of (NZB x NZW)F1 mice through effects mediated by a modulated immune system. Since neutralizing IL-6 antibody treatment did not prevent the development of glomerulonephritis, it is unlikely that increased IL-6 production plays a role in the pathogenesis of lupus nephritis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (4.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216. [PubMed]
  • Howie JB, Helyer BJ. The immunology and pathology of NZB mice. Adv Immunol. 1968;9:215–266. [PubMed]
  • Jevnikar AM, Singer GG, Brennan DC, Xu HW, Kelley VR. Dexamethasone prevents autoimmune nephritis and reduces renal expression of Ia but not costimulatory signals. Am J Pathol. 1992 Sep;141(3):743–751. [PMC free article] [PubMed]
  • Cavallo T, Granholm NA. Bacterial lipopolysaccharide transforms mesangial into proliferative lupus nephritis without interfering with processing of pathogenic immune complexes in NZB/W mice. Am J Pathol. 1990 Oct;137(4):971–978. [PMC free article] [PubMed]
  • Kim C, Siminovitch KA, Ochi A. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment. J Exp Med. 1991 Dec 1;174(6):1431–1437. [PMC free article] [PubMed]
  • Widmer MB. Inhibition of cytokine function: potential in autoimmune disease. Curr Opin Biotechnol. 1991 Dec;2(6):872–876. [PubMed]
  • Jacob CO. Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch? Immunol Today. 1992 Apr;13(4):122–125. [PubMed]
  • Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1988 Jan 28;331(6154):356–358. [PubMed]
  • Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep;52(3):421–434. [PubMed]
  • Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988 Nov 1;141(9):3050–3054. [PubMed]
  • Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989 Dec 1;143(11):3470–3475. [PubMed]
  • Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol. 1992;10:13–49. [PubMed]
  • Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987 Sep 1;166(3):798–803. [PMC free article] [PubMed]
  • Ozmen L, Gribaudo G, Fountoulakis M, Gentz R, Landolfo S, Garotta G. Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol. 1993 Apr 1;150(7):2698–2705. [PubMed]
  • Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989 Dec;61(6):588–602. [PubMed]
  • Baroja ML, Ceuppens JL, Van Damme J, Billiau A. Cooperation between an anti-T cell (anti-CD28) monoclonal antibody and monocyte-produced IL-6 in the induction of T cell responsiveness to IL-2. J Immunol. 1988 Sep 1;141(5):1502–1507. [PubMed]
  • Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 1988 Mar 1;167(3):1253–1258. [PMC free article] [PubMed]
  • Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med. 1988 Apr 1;167(4):1417–1427. [PMC free article] [PubMed]
  • Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990 Dec;11(12):443–449. [PubMed]
  • Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989 Dec 15;143(12):3949–3955. [PubMed]
  • Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl. 1993 Jan;39:S71–S75. [PubMed]
  • Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547–7551. [PMC free article] [PubMed]
  • Heremans H, Dillen C, Put W, Van Damme J, Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol. 1992 Sep;22(9):2395–2401. [PubMed]
  • Gunn HC, Ryffel B. Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine. Clin Nephrol. 1986;25 (Suppl 1):S189–S192. [PubMed]
  • Ryffel B, Kammüller M, Robison R, Myers L. Pathology induced by interleukin-6. Toxicol Lett. 1992 Dec;64-65 Spec No:311–319. [PubMed]
  • Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR, Simpson RJ. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9679–9683. [PMC free article] [PubMed]
  • Odermatt B, Eppler M, Leist TP, Hengartner H, Zinkernagel RM. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8252–8256. [PMC free article] [PubMed]
  • Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253–278. [PubMed]
  • Noma T, Mizuta T, Rosén A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett. 1987 Jul;15(3):249–253. [PubMed]
  • Le JM, Fredrickson G, Reis LF, Diamantstein T, Hirano T, Kishimoto T, Vilcek J. Interleukin 2-dependent and interleukin 2-independent pathways of regulation of thymocyte function by interleukin 6. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8643–8647. [PMC free article] [PubMed]
  • Garman RD, Jacobs KA, Clark SC, Raulet DH. B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7629–7633. [PMC free article] [PubMed]
  • Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 1988 Mar 1;167(3):1253–1258. [PMC free article] [PubMed]
  • Houssiau FA, Coulie PG, Olive D, Van Snick J. Synergistic activation of human T cells by interleukin 1 and interleukin 6. Eur J Immunol. 1988 Apr;18(4):653–656. [PubMed]
  • Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, Köck A, Micksche M, Malejczyk J, Schauer E, et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989 Aug 15;143(4):1206–1209. [PubMed]
  • Wuthrich RP, Yui MA, Mazoujian G, Nabavi N, Glimcher LH, Kelley VE. Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol. 1989 Jan;134(1):45–51. [PMC free article] [PubMed]
  • Wuthrich RP, Jevnikar AM, Takei F, Glimcher LH, Kelley VE. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am J Pathol. 1990 Feb;136(2):441–450. [PMC free article] [PubMed]
  • Jevnikar AM, Wuthrich RP, Takei F, Xu HW, Brennan DC, Glimcher LH, Rubin-Kelley VE. Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. Kidney Int. 1990 Sep;38(3):417–425. [PubMed]
  • Wuthrich RP. Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis. Kidney Int. 1992 Oct;42(4):903–914. [PubMed]
  • Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11:571–611. [PubMed]
  • Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452. [PubMed]
  • Jacob CO, Hwang F, Lewis GD, Stall AM. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine. 1991 Nov;3(6):551–561. [PubMed]
  • Davidson WF, Calkins C, Hügins A, Giese T, Holmes KL. Cytokine secretion by C3H-lpr and -gld T cells. Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+ T cells. J Immunol. 1991 Jun 15;146(12):4138–4148. [PubMed]
  • Deusch K, Fernandez-Botran R, Konstadoulakis M, Baur K, Schwartz RS, Madaio MP. Autoreactive T cells from MRL-lpr/lpr mice secrete multiple lymphokines and induce the production of IgG anti-DNA antibodies. J Autoimmun. 1991 Aug;4(4):563–576. [PubMed]
  • Bloom RD, Florquin S, Singer GG, Brennan DC, Kelley VR. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int. 1993 May;43(5):1000–1009. [PubMed]
  • Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol. 1987 Jan 1;138(1):157–163. [PubMed]
  • Quinn DG, Fennell JS, Sheils O, Gaffney EF, Feighery CF. Effect of cyclosporin on immune complex deposition in murine glomerulonephritis. Immunology. 1991 Apr;72(4):550–554. [PMC free article] [PubMed]
  • Floege J, Eng E, Young BA, Johnson RJ. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int Suppl. 1993 Jan;39:S47–S54. [PubMed]
  • Radeke HH, Resch K. The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system. Clin Investig. 1992 Sep;70(9):825–842. [PubMed]
  • Sterzel RB, Schulze-Lohoff E, Marx M. Cytokines and mesangial cells. Kidney Int Suppl. 1993 Jan;39:S26–S31. [PubMed]
  • Waldherr R, Cuzic S, Noronha IL. Pathology of the human mesangium in situ. Clin Investig. 1992 Sep;70(9):865–874. [PubMed]
  • Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, Coleman DL. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 1990 Aug;38(2):249–257. [PubMed]
  • van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, van Es LA, Daha MR. Soluble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells. Kidney Int. 1993 Mar;43(3):544–553. [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...